Ozempic Side Effects: Positive Outcomes & Genetic Insights

Last reviewed: June 2, 2026

Last updated: June 2, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Beyond appetite suppression, GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) produce measurable metabolic and cardiovascular benefits. Clinical trials show improvements in blood pressure, inflammatory markers, and cardiovascular event risk—outcomes that extend far beyond weight management alone.

Not all patients experience the same constellation of benefits. Genetic variation in GLP-1 receptor pathways and related metabolic genes explains why some individuals see pronounced cardioprotective effects while others prioritize glycemic control. Understanding your individual biomarker profile supports more informed conversations with your provider about expected outcomes.

Cardiovascular Benefits Beyond Weight Loss

The SUSTAIN-6 trial demonstrated that semaglutide reduced cardiovascular events by 26% in patients with type 2 diabetes and prior cardiovascular disease. Blood pressure reductions of 3-5 mmHg occur independently of weight loss, suggesting direct vascular benefits from GLP-1 pathway activation.

These cardioprotective effects emerge partly through reduced systemic inflammation and improved endothelial function. Patients with established atherosclerotic disease or hypertension may experience proportionally greater cardiovascular benefit than those without baseline cardiovascular compromise.

How Genetic Variation Shapes Individual Response Patterns

Four key genetic variants influence how your body responds to GLP-1 therapies. The GLP1R rs6923761 variant affects receptor sensitivity, while GIPR rs1800437 influences glucose-dependent insulin secretion. FTO rs9939609 and MC4R rs17782313 correlate with metabolic rate and appetite regulation pathways.

These predispositions do not determine outcomes but may help contextualize why some patients achieve rapid weight loss while others see slower reductions paired with stronger blood sugar improvements. Genetic testing can support a more nuanced provider conversation about realistic timelines and expected benefits.

Genetic Variant	Pathway Role	Relevance to GLP-1 Response
GLP1R rs6923761	GLP-1 receptor expression and signaling	May influence receptor sensitivity and cardiovascular responsiveness
GIPR rs1800437	Glucose-dependent insulin secretion	Affects secondary insulin pathway activation and glycemic control
FTO rs9939609	Energy expenditure and metabolic rate	Influences baseline metabolic efficiency and appetite signaling
MC4R rs17782313	Central appetite and satiety regulation	Predicts potential magnitude of appetite suppression benefit

Metabolic Markers That Improve Independent of Weight Change

Insulin sensitivity and hepatic fat content improve within weeks of starting GLP-1 therapy, often before significant weight loss. Fasting glucose levels typically decline 20-30 mg/dL in patients with type 2 diabetes, and HbA1c reductions average 1-2 percentage points depending on baseline glycemic control.

Triglyceride levels often decline 15-25%, and C-reactive protein (a marker of systemic inflammation) decreases in most patients. These changes suggest pleiotropic benefits—meaning GLP-1 activation produces multiple independent favorable effects across different metabolic systems simultaneously.

Safety Considerations and Who Benefits Most

GLP-1 agonists are not appropriate for all patients. Contraindications include personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia type 2, and type 1 diabetes (without specialist oversight). Gastrointestinal side effects—nausea, constipation, delayed gastric emptying—occur in 30-50% of users, though typically diminish with dose titration.

Patients with existing cardiovascular disease, hypertension, or metabolic syndrome often realize the largest absolute benefit-to-risk ratio. A qualified healthcare provider should evaluate your medical history, current medications, and metabolic profile to determine whether GLP-1 therapy and which formulation aligns with your clinical goals.

How PlexusDx Supports a More Personalized Approach

The Precision Peptide Genetic Test identifies predispositions in four key peptide pathway genes that influence how your body responds to GLP-1 and GLP-1/GIP combination therapies. This test may help provide context for why certain metabolic or appetite benefits might emerge more prominently in your case compared to others, supporting a more personalized treatment discussion with your provider.

Genetic predispositions do not predict exact medication response or guarantee specific outcomes. Instead, variants in GLP1R, GIPR, FTO, and MC4R reveal which regulatory pathways may be more or less responsive to activation, helping explain individual variation in weight loss speed, appetite suppression intensity, and metabolic improvements.

When combined with baseline biomarkers (fasting glucose, insulin, lipid panel, inflammation markers), genetic insights from the Precision Peptide test can support a more informed conversation with your healthcare provider about realistic timelines, which formulation (compounded semaglutide injection, oral semaglutide, tirzepatide, or GLP-Squared dual compound) may align best with your pathway predispositions, and what outcomes to prioritize.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.